Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders.
Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.
Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) has successfully completed a Phase 2a proof of concept in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID) In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticalsfor epilepsy. In January 2018, Addex and Indivior have entered into an exclusive partnership to identify new GABAB PAMs to be developed as potential new treatments of addiction. Under the terms of the agreement, Addex has retained rights to certain indications such as Charcot-Marie-Tooth Type 1A (CMT1A) disease.
Other discovery programs include mGlu4 PAM for Parkinson’s disease, mGlu7 NAM for anxiety disorders such as post-traumatic stress syndrome (PTSD), TrkB PAM and mGluR3 PAM for neurodegenerative disorders.
Founded in 2002, Addex is headquartered in Geneva and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN.